Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

FibroBiologics, Inc. Common Stock

Healthcare US FBLG

1.03USD
-0.04(3.74%)

Last update at 2026-06-05T20:00:00Z

Day Range

0.991.07
LowHigh

52 Week Range

1.0326.53
LowHigh

Fundamentals

  • Previous Close 1.07
  • Market Cap6.90M
  • Volume74842
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.40500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-8.4

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -11.16100M -16.48500M -5.12100M -1.58200M -1.16900M
Minority interest - - - - -
Net income -11.16100M -16.48500M -5.12100M -1.58200M -1.16900M
Selling general administrative 9.23M 6.52M 3.32M 1.06M 0.50M
Selling and marketing expenses - 0.69M - - -
Gross profit -0.57300M -0.43700M - - -
Reconciled depreciation 0.57M 0.44M 0.09M 0.00000M -
Ebit -11.14100M -16.33800M - - -
Ebitda -10.56800M -15.90100M - - -
Depreciation and amortization 0.57M 0.44M - - 1.17M
Non operating income net other - - - - -
Operating income -13.73700M -8.88900M -4.46700M -1.57800M -1.16900M
Other operating expenses 13.74M 8.89M - - 1.17M
Interest expense 0.02M 0.15M 0.65M 0.00400M -
Tax provision - - - - -
Interest income 0.25M 0.00000M - - -
Net interest income 0.23M -0.14700M -0.65400M -0.00400M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 13.74M 8.89M 4.47M 1.58M 1.17M
Cost of revenue 0.57M 0.44M - - -
Total other income expense net 2.58M -7.59600M - - -
Discontinued operations - - - - -
Net income from continuing ops -11.16100M -16.48500M -5.12100M -1.58200M -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 16.45M 11.82M 4.82M 0.47M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.24M 0.05M 0.03M 0.02M -
Total liab 13.71M 10.57M 8.82M 1.76M -
Total stockholder equity 2.73M 1.25M -3.99600M -1.29000M -
Deferred long term liab - - - - -
Other current liab 0.46M 7.38M 0.54M - -
Common stock - 0.00100M - - 1.17M
Capital stock 0.00000M 0.00100M 0.00100M 0.00000M -
Retained earnings -35.51800M -24.35700M -7.87200M -2.75100M -1.16900M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 13.98M 9.16M 2.27M 0.41M -
Cash and equivalents - - - - -
Total current liabilities 12.73M 9.18M 7.07M 1.76M -
Current deferred revenue - - - - -
Net debt -3.43200M -7.41600M 3.19M 0.89M -
Short term debt 9.57M 0.36M - - -
Short long term debt 9.17M - 5.45M 1.30M -
Short long term debt total 10.55M 1.75M - - -
Other stockholder equity 38.25M 25.61M - - -
Property plant equipment - - - - -
Total current assets 14.23M 9.21M 2.62M 0.47M -
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.70M 1.44M 0.76M 0.23M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00000M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 2.22M 2.61M 2.20M 0.00000M -
Capital lease obligations 1.39M 1.75M 2.07M 0.00000M -
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.18400M -0.49500M 0.00000M - -
Change to liabilities - - - - -
Total cashflows from investing activities -0.18400M -0.49500M - - -
Net borrowings 9.40M 0.30M - - -
Total cash from financing activities 16.91M 13.79M 5.92M 1.82M 1.17M
Change to operating activities - - - - -
Net income -11.16100M -16.48500M -5.12100M -1.58200M -1.16900M
Change in cash 4.82M 6.90M 1.86M 0.41M -
Begin period cash flow 9.16M 2.27M 0.41M 0.00000M -
End period cash flow 13.98M 9.16M 2.27M 0.41M -
Total cash from operating activities -11.90100M -6.40100M -4.06600M -1.41000M -1.16900M
Issuance of capital stock 7.51M 16.14M 2.15M 0.00000M -
Depreciation 0.57M 0.44M 0.09M 0.00000M -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 9.40M 13.49M - - 1.17M
Change to netincome - - - - -
Capital expenditures 0.18M 0.49M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.56M 0.49M 0.31M 0.17M -
Stock based compensation 2.22M 1.76M 0.27M 0.00000M -
Other non cash items -4.09100M 7.39M 0.39M - -
Free cash flow -12.08500M -6.89600M -4.06600M -1.41000M -1.16900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
FBLG
FibroBiologics, Inc. Common Stock		 -0.04 3.74% 1.03 - - - 1.11
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

FibroBiologics, Inc. Common Stock

455 East Medical Center Boulevard, Houston, TX, United States, 77598

Key Executives

Name Title Year Born
Mr. Peter O'Heeron Founder, Chairman & CEO 1964
Mr. Mark C. Andersen C.F.A., CPA, M.B.A. Chief Financial Officer 1972
Dr. Hamid Khoja Ph.D. Chief Scientific Officer 1970
Mr. Ruben A. Garcia General Counsel NA
Mr. Peter O'Heeron Founder, Chairperson & CEO 1964
Mr. Ruben A. Garcia J.D. General Counsel 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.